# A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative Colitis

> **NCT01551290** · PHASE3 · COMPLETED · sponsor: **Xian-Janssen Pharmaceutical Ltd.** · enrollment: 99 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01551290
- **Lead sponsor:** Xian-Janssen Pharmaceutical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-03
- **Final completion:** 2014-10
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2015-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01551290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01551290, "A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01551290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*